A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult participants with moderately to severely active Ulcerative Colitis (UC) or Crohn's Disease (CD) under real-world settings. CD and UC are the main type of Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

NCT Number	NCT07242248
Lead Sponsor	Janssen-Cilag Ltd.
Conditions	Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
Enrollment	220 participants
Start Date	2025-11-17
Primary Completion	2029-03-05 (estimated)
Study Completion	2029-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-07-06